Veradermics, Incorporated
NYSE:MANE · New York Stock Exchange
-$1.13 today
Vol 0.82M · Avg 0.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
57.8%
avg -34.5%
ROIC
-50.4%
avg -70.6%
ROA
-45.9%
avg -59.9%
Analysis
ROE is currently the strongest return metric at 57.8% versus its period average of -34.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Reid Waldman | CEO & Director | $917,417.00 | — | 31 | — | — |
Timothy Durso | Chief Technical Officer | $658,517.00 | — | 36 | — | — |
Dominic Carrano | CFO & Treasurer | $633,264.00 | — | 40 | — | — |
Aron Shapiro | Vice President of Clinical Development & Regulatory Affairs | — | — | 48 | — | — |
Brian Trautman | Director of CMC Project Management | — | — | — | — | — |
Karl Pruss | Senior Director of Manufacturing Sciences & Technology | — | — | — | — | — |
Mark Neumann | Chief Commercial and Strategy Officer | — | — | 62 | — | — |
Michael Murphy | VP of Project & Program Management of Business Technology and Chief of Staff | — | — | — | — | — |
Michael V. Greco | General Counsel & Secretary | — | — | 53 | — | — |
Barbara Szymaszek | Director of Clinical Operations | — | — | — | — | — |
Michael Smolinski | Vice President of Development & Scientific Operations | — | — | 48 | — | — |
Elizabeth Lindemann | Associate Director of Medical Affairs | — | — | — | — | — |
Erika Sipperly | Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.05B
Abeona Therapeutics Inc.
NASDAQ:ABEO
$324.30M
Ovid Therapeutics Inc.
NASDAQ:OVID
$309.27M
Cybin Inc. Common Stock
NASDAQ:HELP
$225.02M
Tharimmune, Inc.
THAR
$139.94M
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
$110.57M
Lisata Therapeutics, Inc.
LSTA
$32.56M
XTL Biopharmaceuticals Ltd.
XTLB
$5.69M
Adial Pharmaceuticals, Inc.
ADIL
$2.68M
Dermata Therapeutics, Inc.
DRMA
$863,260.00
Who manages MANE?
Veradermics, Incorporated (MANE) lists 13 active executives. The top listed executive is Aron Shapiro, Vice President of Clinical Development & Regulatory Affairs.
Explore More
Continue the stock analysis
Jump to another research area for this company.